NEW YORK (GenomeWeb) – Rosetta Genomics said today that it intends to sell its PersonalizeDx business as part of an ongoing effort to focus on its microRNA-based thyroid nodule classification assay, RosettaGx Reveal.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.